Sign Out
Symptoms and Signs: There are no data available from clinical trials on overdose with RELVAR ELLIPTA.
An overdose of RELVAR ELLIPTA may produce signs and symptoms due to the individual components' actions, including those seen with overdose of other beta2-agonists and consistent with the known inhaled corticosteroid class effects (see Precautions).
Treatment: There is no specific treatment for an overdose with RELVAR ELLIPTA. If overdose occurs, the patient should be treated supportively with appropriate monitoring as necessary.
Cardioselective beta-blockade should only be considered for profound vilanterol overdose effects that are clinically concerning and unresponsive to supportive measures. Cardioselective beta-blocking drugs should be used with caution in patients with a history of bronchospasm.
Further management should be as clinically indicated or as recommended by the national poisons centre, where available.
